| 1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34.
|
| 2. |
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 2014, 74(11): 2913-2921.
|
| 3. |
Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin, 2001, 51(1): 15-36.
|
| 4. |
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350(12): 1200-1210.
|
| 5. |
Washington K, Berlin J, Branton Ph, et al. Protocol for the examination of specimens from patients with carcinoma of the pancreas. 2017. 6. Avalaible at: http://www.cap.org.
|
| 6. |
The Royal College of Pathologists. London. Dataset for the histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. 2017. 3. Available at: http://www.rcpath.org.
|
| 7. |
Strobel O, Hank T, Hinz U, et al. Pancreatic cancer surgery: The new R-status counts. Ann Surg, 2017, 265(3): 565-573.
|
| 8. |
Delpero JR, Jeune F, Bachellier P, et al. Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: Updates from a French prospective multicenter study. Ann Surg, 2017, 266(5): 787-796.
|
| 9. |
Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg, 2019, 269(3): 520-529.
|
| 10. |
Jang JY, Kang MJ, Heo JS, et al. A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg, 2014, 259(4): 656-664.
|
| 11. |
NCCN. NCCN Clinical practice Guidelines in oncology: pancreatic adenocacinoma, Version 2.2020. 2020.12. Available at: http://www.nccn.org.
|
| 12. |
Qian LH, Xie JJ, Xu ZW, et al. The necessity of dissection of No. 14 lymph nodes to patients with pancreatic ductal adenocarcinoma based on the embryonic development of the head of the pancreas. Front Oncol, 2020, 10: 1343.
|
| 13. |
Chen Y, Tan C, Mai G, et al. Resection of pancreatic tumors involving the anterior surface of the superior mesenteric/portal veins axis: an alternative procedure to pancreaticoduodenectomy with vein resection. J Am Coll Surg, 2013, 217(4): e21-e28.
|
| 14. |
Chen Y, Wang X, Ke N, et al. Inferior mesenteric vein serves as an alternative guide for transection of the pancreatic body during pancreaticoduodenectomy with concomitant vascular resection: a comparative study evaluating perioperative outcomes. Eur J Med Res, 2014, 19(1): 42.
|
| 15. |
Gall TM, Jacob J, Frampton AE, et al. Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer. JAMA Surg, 2014, 149(5): 482-485.
|
| 16. |
Chen Y, Tan C, Zhang H, et al. Novel entirely continuous running suture of two-layer pancreaticojejunostomy using only one polypropylene monofilament suture. J Am Coll Surg, 2013, 216(2): e17-e21.
|
| 17. |
Du B, Wang X, Wang X, et al. A rare case of central pancreatectomy for isolated complete pancreatic neck transection trauma. BMC Surg, 2019, 19(1): 91.
|
| 18. |
Li X, Guo C, Li Q, et al. Association of modified-FOLFIRINOX-regimen-based neoadjuvant therapy with outcomes of locally advanced pancreatic cancer in Chinese population. Oncologist, 2019, 24(3): 301-e393.
|
| 19. |
Nagakawa Y, Sahara Y, Hosokawa Y, et al. Clinical impact of neoadjuvant chemotherapy and chemoradiotherapy in borderline resectable pancreatic cancer: Analysis of 884 patients at facilities specializing in pancreatic surgery. Ann Surg Oncol, 2019, 26(6): 1629-1636.
|
| 20. |
Yoo C, Shin SH, Kim KP, et al. Clinical outcomes of conversion surgery after neoadjuvant chemotherapy in patients with borderline resectable and locally advanced unresectable pancreatic cancer: a single-center, retrospective analysis. Cancers (Basel), 2019, 11(3): E278.
|
| 21. |
Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial. JAMA Oncol, 2018, 4(7): 963-969.
|
1/5
WeChat